Kappadione

DB09332ApprovedSmall molecule

Kappadione is a Vitamin K derivative (chemically, it is menadiol sodium diphosphate), previously approved by FDA prior to 1982 and marketed by Lilly Marketing for this drug has been discontinued... It has been found to have carcinogenic potential in mammalian cells as well as cytotoxic properties.

Chemical structure of Kappadione
Mechanism
Curator reviewed · 1 reference
Primary indication
Anticoagulant-induced prothrombin deficiency caused by coumadin or indanedione derivatives, prophylaxis and therapy of hemorrhagic disease of the newborn, hypoprothrombinemia due to antibacterial therapy, hypoprothrombinemia secondary to factors limiting absorption or synthesis of vitamin K (for...Curator reviewed
Formula / weight
C11H8Na4O8P2 · 422.084 g/mol (avg)
Also known as
Menadiol sodium diphosphate

Resolves to

Clinical / RWD
Structure
InChIKeyGZBACHSOZNEZOG-UHFFFAOYSA-JSMILES[Na+].[Na+].[Na+].[Na+].CC1=C(OP([O-])([O-])=O)C2=CC=CC=C2C(OP([O-])([O-])=O)=C1

What you can answer from here — as of April 02, 2025

7Protein targetsEach mapped to UniProt, with action and pharmacological action
Listed above
1Clinical trialPhase, status and sponsor resolved per trial
Sign in
23+ReferencesStructured and connected to the statements they support
Sign in

Which drugs share a target with Kappadione, and which of those have an active Phase 3 trial?

Create a free account or log in to explore the full data card.

Create Account